Skip to content

Study on the Effect and Mechanism of Modified Zexie Decoction in Intervening Grade I Hypertension with Phlegm-Dampness Retention Syndrome Based on the Theory of "Spleen Governing Transportation and Transformation"

Study on the Effect and Mechanism of Modified Zexie Decoction in Intervening Grade I Hypertension with Phlegm-Dampness Retention Syndrome Based on the Theory of "Spleen Governing Transportation and Transformation"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001480
Enrollment
Unknown
Registered
2026-06-10
Start date
2023-01-01
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Grade I Essential Hypertension

Interventions

Control Group:General Treatment: Guidance on healthy lifestyle modification (including appropriate daily physical exercise, maintaining an ideal body weight as much as possible, reducing dietary sodiu
Treatment Group:Modified Zexie Decoction

Sponsors

Jiaxing Second Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Age = 30 years and = 60 years, disease duration < 3 months, with no gender restriction.2) Meeting the aforementioned western medical diagnostic criteria and traditional Chinese medicine (TCM) syndrome differentiation criteria. The TCM diagnosis shall be determined by two TCM physicians at or above the attending level.3) No other immune-related medications have been taken within 1 month prior to treatment.4) The patient and their family have been fully informed of the study and provided written informed consent. Note: Only those who meet all the above 4 items can be enrolled in this study.

Exclusion criteria

Exclusion criteria: 1) Secondary hypertension.2) Severe cardiac insufficiency.3) Severe hepatic and renal insufficiency.4) Pregnant or lactating women.5) Previous history of cerebrovascular disease.6) Immune-related diseases.7) Patients unable to take medication as prescribed or uncooperative with treatment. Note: Patients meeting any of the above items will be excluded.

Design outcomes

Primary

MeasureTime frame
Evaluation of Curative Effect on Blood Pressure;

Secondary

MeasureTime frame
Therapeutic Effect on TCM Syndromes;24-hour Ambulatory Blood Pressure Monitoring;Changes in Biochemical Indicators;

Countries

China

Contacts

Public ContactNinghua Jiang

Jiaxing Second Hospital

jiangnhnh@163.com13586484565

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 29, 2026